Inovio Pharma (Nasdaq: INO) announced that its DNA-based monoclonal antibody (dMAb) targeting dengue virus provided protection against a lethal dengue ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE